MedTrace Logo

Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease

NCT00103714 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-10-20

No results posted yet for this study

Summary

The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in patients with cystic fibrosis (CF) lung disease.

Conditions

Interventions

DRUG

denufosol tetrasodium (INS37217)

Sponsors & Collaborators

Principal Investigators

  • Amy Schaberg, BSN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-08-31
Completion
2005-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00103714 on ClinicalTrials.gov